A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage) for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence.

Trial Profile

A Phase 2, Multicenter, Randomized, Single-Blind Study of Vitespen (HSPPC-96, Oncophage) for Immune Response Assessment Following Treatment of Patients With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Vitespen (Primary)
  • Indications Renal cell carcinoma
  • Focus Pharmacodynamics; Registrational
  • Sponsors Agenus
  • Most Recent Events

    • 20 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.
    • 20 Aug 2012 Actual end date (1 Aug 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top